Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Hypertension Clear all
Recruiting Not applicable Interventional

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

NCT05844384
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Nanodropper, Regular dropper
Device
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 26, 2026, 7:31 PM EDT
Terminated Not applicable Interventional

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

NCT04467879
View directory record Official record
Conditions
Hypertension, Systolic
Interventions
Zona Plus Device, Control Device
Device
Lead sponsor
Zona Health, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
St Louis, Missouri • Charlotte, North Carolina • Goldsboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00818883
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
50
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional Results available

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

NCT01560975
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

Right Ventricular Pacing in Pulmonary Arterial Hypertension

NCT04194632
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions
Temporary right ventricular pacing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Utilizing Consumer Health Informatics to Support Management of Hypertension by Clinical Pharmacists in Primary Care

NCT02898584
View directory record Official record
Conditions
Hypertension
Interventions
BP Track
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 26, 2026, 7:31 PM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

Hydrus® Microstent New Enrollment Post-Approval Study

NCT04553523
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Microstent, Cataract surgery, Monofocal IOL
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
22
States / cities
Irvine, California • Sacramento, California • Loveland, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

The Northwest Coalition for Primary Care Practice Support

NCT02839382
View directory record Official record
Conditions
Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
Interventions
Coaching, Educational Outreach, Site Visits
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions
PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions

NCT06557005
View directory record Official record
Conditions
Hypertension, Diabetes, Postpartum, Pregnancy, Anxiety, Depression, Obesity
Interventions
Facilitated Transition to Primary Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BP PAL - Hypertension Chat Bot Pilot

NCT05571410
View directory record Official record
Conditions
Hypertension
Interventions
HTN Chat bot
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Health Coach Program to Improve Chronic Disease Outcomes Following an Emergency Department Visit

NCT02386540
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension
Interventions
Health Coaching
Behavioral
Lead sponsor
Alameda County Medical Center
Other
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients

NCT01399489
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension, Diabetes
Interventions
Exercise training
Behavioral
Lead sponsor
Springfield College
Other
Eligibility
35 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783
View directory record Official record
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 26, 2026, 7:31 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional

Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.

NCT06287580
View directory record Official record
Conditions
Essential Hypertension, Older Adults
Interventions
chlorthalidone, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

NCT05925569
View directory record Official record
Conditions
Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions
Best Practice Advisory Computerized Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
12,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Completed No phase listed Observational

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

NCT02151318
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 26, 2026, 7:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure

NCT00001176
View directory record Official record
Conditions
Hyperaldosteronism, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1981 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Biorepository and Registry

NCT04808596
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 26, 2026, 7:31 PM EDT